Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Raltegravir (RAL) and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) efficiently block viral replication in vitro and suppress viremia in patients. These small molecules bind to the IN active site, causing it to disengage from the deoxyadenosine at the 3 end of viral DNA. The emergence of viral strains that are highly resistant to RAL underscores the pressing need to develop INSTIs with improved resistance profiles. Herein, we show that the candidate second-generation drug dolutegravir (DTG, S/GSK1349572) effectively inhibits a panel of HIV-1 IN variants resistant to first-generation INSTIs. To elucidate the structural basis for the increased potency of DTG against RAL-resistant INs, we determined crystal structures of wild-type and mutant prototype foamy virus intasomes bound to this compound. The overall IN binding mode of DTG is strikingly similar to that of the tricyclic hydroxypyrrole MK2048. Both second-generation INSTIs occupy almost the same physical space within the IN active site and make contacts with the 4–2 loop of the catalytic core domain. The extended linker region connecting the metal chelating core and the halobenzyl group of DTG allows it to enter farther into the pocket vacated by the displaced viral DNA base and to make more intimate contacts with viral DNA, compared with those made by RAL and other INSTIs. In addition, our structures suggest that DTG has the ability to subtly readjust its position and conformation in response to structural changes in the active sites of RAL-resistant INs.

[1]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[2]  Yves Pommier,et al.  HIV-1 IN inhibitors: 2010 update and perspectives. , 2009, Current topics in medicinal chemistry.

[3]  Y. Pommier,et al.  Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143 , 2011, AIDS.

[4]  T Honma,et al.  Crystallographic Approach to Identification of Cyclin-dependent Kinase 4 (CDK4)-specific Inhibitors by Using CDK4 Mimic CDK2 Protein* , 2001, The Journal of Biological Chemistry.

[5]  Ian Collins,et al.  A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. , 2007, Journal of molecular biology.

[6]  D. Cruickshank,et al.  Remarks about protein structure precision. , 1999, Acta crystallographica. Section D, Biological crystallography.

[7]  Y. Pommier,et al.  Resistance to Integrase Inhibitors , 2010, Viruses.

[8]  T. Schneider,et al.  Objective comparison of protein structures: error-scaled difference distance matrices. , 2000, Acta crystallographica. Section D, Biological crystallography.

[9]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[10]  L. Stuyver,et al.  Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates , 2010, Antimicrobial Agents and Chemotherapy.

[11]  R. Huber,et al.  Structure-based optimization of novel azepane derivatives as PKB inhibitors. , 2004, Journal of medicinal chemistry.

[12]  C. Charpentier,et al.  Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy * , 2008, HIV medicine.

[13]  Hongtao Xu,et al.  Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor , 2010, Journal of Virology.

[14]  Dominique Schols,et al.  Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. , 2010, Virology.

[15]  Amy S. Espeseth,et al.  Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Engelman,et al.  Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.

[17]  Goedele N. Maertens,et al.  The mechanism of retroviral integration through X-ray structures of its key intermediates , 2010, Nature.

[18]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[19]  Luba Tchertanov,et al.  Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[20]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[21]  Y. Pommier,et al.  2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. , 2008, Journal of medicinal chemistry.

[22]  Satoru Ikeda,et al.  Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. , 2006, Journal of medicinal chemistry.

[23]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.

[24]  Yves Pommier,et al.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. , 2010, Biochemistry.

[25]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[26]  D. Langley,et al.  The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. , 2008, Biochemistry.

[27]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.

[28]  Shigeru Miki,et al.  In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor , 2010, Antimicrobial Agents and Chemotherapy.

[29]  Maxwell D. Cummings,et al.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.

[30]  A. Engelman,et al.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro , 1992, Journal of virology.

[31]  Robert Craigie,et al.  Retroviral DNA integration: reaction pathway and critical intermediates , 2006, The EMBO journal.

[32]  A. Skalka,et al.  Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases , 1992, Molecular and cellular biology.

[33]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[34]  P. Roversi,et al.  Functional and structural characterization of the integrase from the prototype foamy virus , 2008, Nucleic acids research.

[35]  P. Cherepanov.  LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro , 2006, Nucleic acids research.

[36]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.